Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?

Hoffman RM, Roberts RG, Barry MJ.

J Gen Intern Med. 2011 Jul;26(7):798-801. doi: 10.1007/s11606-010-1622-4. Epub 2011 Jan 11.

2.

Pharmacological approaches to reducing the risk of prostate cancer.

Rittmaster RS, Fleshner NE, Thompson IM.

Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Review.

PMID:
19200641
3.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
4.

Chemoprevention using dutasteride: the REDUCE trial.

Gomella LG.

Curr Opin Urol. 2005 Jan;15(1):29-32. Review.

PMID:
15586026
5.

Should finasteride be used to prevent prostate cancer?

Fleshner N, Kulkarni G.

Curr Treat Options Oncol. 2006 Sep;7(5):346-54. Review.

PMID:
16904051
6.

Chemoprevention of prostate cancer.

Stephenson AJ, Abouassaly R, Klein EA.

Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents. doi: 10.1016/j.ucl.2009.11.003. Review.

PMID:
20152515
7.

Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

Hudak SJ, Hernandez J, Thompson IM.

Clin Interv Aging. 2006;1(4):425-31. Review.

8.

5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.

Wilt TJ, Macdonald R, Hagerty K, Schellhammer P, Tacklind J, Somerfield MR, Kramer BS.

BJU Int. 2010 Nov;106(10):1444-51. doi: 10.1111/j.1464-410X.2010.09714.x. Review. Erratum in: BJU Int. 2011 Jan;107(2):344.

9.

Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.

Azzouni F, Mohler J.

Urology. 2012 Jun;79(6):1197-205. doi: 10.1016/j.urology.2012.01.024. Epub 2012 Mar 23. Review.

PMID:
22446342
10.

Dutasteride for the treatment of prostate-related conditions.

Slater S, Dumas C, Bubley G.

Expert Opin Drug Saf. 2012 Mar;11(2):325-30. doi: 10.1517/14740338.2012.658040. Epub 2012 Feb 8. Review.

PMID:
22316171
11.

Update on prostate cancer chemoprevention.

Lowe JF, Frazee LA.

Pharmacotherapy. 2006 Mar;26(3):353-9. Review.

PMID:
16503715
12.

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

Reed AB, Parekh DJ.

Curr Opin Urol. 2009 May;19(3):238-42. doi: 10.1097/MOU.0b013e328329eb29. Review.

PMID:
19318950
13.

Prostate cancer: a serious disease suitable for prevention.

Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH.

BJU Int. 2009 Apr;103(7):864-70. doi: 10.1111/j.1464-410X.2008.08206.x. Review.

14.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P; American Society of Clinical Oncology Health Services Committee; American Urological Association Practice Guidelines Committee.

J Clin Oncol. 2009 Mar 20;27(9):1502-16. doi: 10.1200/JCO.2008.16.9599. Epub 2009 Feb 24. Review. Erratum in: J Clin Oncol. 2009 Jun 1;27(16):2742.

15.

A review of phase III clinical trials of prostate cancer chemoprevention.

Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK.

Ann R Coll Surg Engl. 2007 Apr;89(3):207-11. Review.

16.

Finasteride.

Chaudhary UB, Turner JS.

Expert Opin Drug Metab Toxicol. 2010 Jul;6(7):873-81. doi: 10.1517/17425255.2010.495944. Review.

PMID:
20536414
17.

Update on chemoprevention for prostate cancer.

Strope SA, Andriole GL.

Curr Opin Urol. 2010 May;20(3):194-7. doi: 10.1097/MOU.0b013e3283381966. Review.

PMID:
20216317
18.

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P; American Society of Clinical Oncology/American Urological Association.

J Urol. 2009 Apr;181(4):1642-57. doi: 10.1016/j.juro.2009.01.071. Epub 2009 Feb 26. Review.

PMID:
19249063
19.

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH.

Eur Urol. 2011 Feb;59(2):183-90. doi: 10.1016/j.eururo.2010.09.035. Epub 2010 Dec 4. Review.

PMID:
21130560
20.

[Role of 5 alpha-reductase inhibitors in the chemoprevention of prostate cancer].

An C, Xu T, Wang XF.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Oct;33(5):582-6. Review. Chinese.

Supplemental Content

Support Center